Additionally, the conjugation of target molecules to these nanocarriers would allow the selective delivery of chemotherapeutic agents to tumor sites with reduced peripheral exposure through a tumor cell surface receptor-mediated targeted effect [17–19]. The gene discussed is CD177; the disease is neoplasm.